Morphological and electrophysiological outcome in prospective intravitreal bevacizumab treatment of macular edema secondary to central retinal vein occlusion

作者：Topcic Ivana Gardasevic^*; Sustar Maja; Brecelj Jelka; Hawlina Marko; Mekjavic Polona Jaki

来源：Documenta Ophthalmologica, 2014, 129(1): 27-38.

DOI：10.1007/s10633-014-9445-y

• Central retinal vein occlusion
• Intravitreal bevacizumab
• Optical cocherence tomography
• Electroretinography
• Photopic negative response
• Pattern electroretinography

To evaluate intravitreal bevacizumab (IVB) treatment in patients with central retinal vein occlusion (CRVO) by spectral domain optical coherence tomography (OCT) and electroretinography (ERG).
Twenty-two CRVO patients were treated with IVB injections and followed for 1 year. Morphological effect of treatment was observed with fluorescent angiography and OCT. Functional effect was followed with best corrected visual acuity (BCVA) and ERG: combined rod-cone response of the standard full-field ERG (dark adapted 3.0 ERG), photopic negative response (PhNR), and pattern ERG (PERG).
Best corrected visual acuity (BCVA) improved by 18.2 letters after 6 months (p a parts per thousand currency sign 0.001) and additional 4.7 letters by the 12th month (p a parts per thousand currency sign 0.001). The central retinal thickness of 829.8 +/- A 256.7 mu m decreased to 398.8 +/- A 230 mu m (p a parts per thousand currency sign 0.001) after 6 months and to 303.7 +/- A 128.9 mu m during the following 6 months (p a parts per thousand currency sign 0.001). The total macular volume (14.4 +/- A 4.2 mm(3)) decreased to 9.6 +/- A 3.2 mm(3) and 8.5 +/- A 2.0 mm(3) after 6 months and 1 year of treatment, respectively (p a parts per thousand currency sign 0.001). Electrophysiological measures improved significantly after 6 months and 1 year of treatment: the a-wave implicit time of dark adapted 3.0 ERG from 25.6 +/- A 2.3 to 24.1 +/- A 2.1 and 24.1 +/- A 2.0 ms (p a parts per thousand currency sign 0.01); the PhNR from -5.9 +/- A 6.6 to -9.4 +/- A 6.1 and -10.4 +/- A 4.6 A mu V (p a parts per thousand currency sign 0.05); the PERG P50 amplitude from 0.2 +/- A 0.3 to 0.9 +/- A 0.6 and 1.1 +/- A 0.6 A mu V (p a parts per thousand currency sign 0.001); and N95 amplitude from 0.4 +/- A 0.6 to 1.2 +/- A 0.9 and 1.6 +/- A 0.9 A mu V (p a parts per thousand currency sign 0.001).
Intravitreal bevacizumab (IVB) treatment of macular edema due to CRVO improved standard morphological measures and the electrophysiological function of outer and inner retinal layers, which was most evident in central retina.

• 出版日期2014-8